U.S. ramps up pharmaceutical oversight in China, FDA official testifies

04/4/2014 | Reuters · Bloomberg

Chinese makers of pharmaceutical ingredients are coming under increasing scrutiny from the U.S. FDA in an effort to bolster the safety of the U.S. drug supply chain, Christopher Hickey, director of the FDA's office in China, said Thursday at a hearing in Washington. The process of adding inspectors and staff in China has started on the back of the FDA's new legal authority and additional funding, he said. "As the number of medical products coming from China has increased, so have the challenges," he told the U.S.-China Economic and Security Review Commission.

View Full Article in:

Reuters · Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX